Screener
Neuropace, Inc. NPCE Return on equity
Return on equity at other companies
Other financials
Where this comes from
Calculated from Neuropace, Inc.’s reported figures.
Based on trailing twelve months.
The source filing: Neuropace, Inc.’s 10-Q, filed August 11, 2026. Open the filing →
- Filed
- Aug 11, 2026, 4:33 PM EDT
- Fiscal quarter
- Q4 FY2030
- Calendar quarter
- Q4 2030
- Accession
- 0001528287-26-000030
FAQ
- What is Neuropace, Inc.'s return on equity?
- Neuropace, Inc. (NPCE) reported return on equity of -122.1% in Q2 2026.
- How has Neuropace, Inc.'s return on equity changed year-over-year?
- Neuropace, Inc.'s return on equity increased by 31.0% year-over-year, from -176.9% to -122.1%.
- What is the long-term trend for Neuropace, Inc.'s return on equity?
- Over 3 years (2022 to 2025), Neuropace, Inc.'s return on equity has grown at a 22.2% compound annual growth rate (CAGR), from -87% to -158.7%.
- What does return on equity mean?
- Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.
Ask your AI about Neuropace, Inc.'s return on equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude